PharmaTimes - January/February 2025

Sound system

It does seem a little odd to suggest that pharma, and all its offshoots, is finally ‘exploding on to the scene’. But it is.

How can something that is used by pretty much everybody on the planet still be emerging from the shadows and only just venturing into the mainstream?

Well, it’s complicated and it’s fragmented and it’s very much like the human condition in that respect. The human condition is the biological mag that industry attempts to navigate but, hitherto, it is the human condition that creates the most insurmountable plot points.

The last decade, however, has witnessed a marked uptick in the ability to see health through a different lens – the prism of difference itself.

There is a new vision for life sciences now, and the great poles of that neo panorama are the realisation that people – in all their kaleidoscopic nuances must be part of the journey (I said the ‘j’ word, forgive me).

The second is technology. Okay, some of it is vaguely threatening (in an existential crisis kind of way) but it is also the conduit through which the appreciation and wonder of difference can be fully leveraged.

The next ten years will propel the pharma rocket ship – and everyone aboard it – into an astonishing climate of clinical colour scapes and intrepid treatment possibilities such as we’ve never seen before.

I know this all sounds like intoxicated New Year optimism, and it is, but absolute truth lies in all of it. Our challenge is to reach out and believe.

Go forth, dear reader

January/February 2025 - magazine highlights

Change is coming

Pharma/NHS shifts are imminent throughout the coming year

Abstract smart

Imperative for AI-powered productivity enhancement

Healthcare balancing

Why early cancer detection for everyone is not always desi...

Give us a clue

Solving the mysteries of neurological conditions

No patient left behind

Promise of N-of-1 studies for rare disease clinical develo...

Design for life

Digital design can streamline pharma regulatory approval

Test of trust

Embracing the AI revolution across pharma communications

On the bright side

Transforming healthcare with automated mass spectrometry